CCL3/MIP-1 alpha Antibody [Unconjugated]

Recombinant Mouse CCL3/MIP‑1 alpha (Catalog #450-MA) chemoattracts BaF3 mouse pro‑B cell line transfected with human CCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant MouseCCL3/MIP‑1 alpha (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse CCL3/MIP‑1 alpha Polyclonal Antibody (Catalog # AB-450-NA). The ND50 is typically 0.3-1 µg/mL.

Effects of neutralizing anti-CCL3 antibody on the number of macrophages at the damaged site and the decrease in area of bone defect on day 4 in uPA+/+ and uPA-/- mice.(A) Microphotographs of immunostaining for F4/80 at the damaged site on day 4 after a femoral bone defect in uPA+/+ and uPA-/- mice treated with normal IgG (Cont) or neutralizing anti-CCL3 antibody (Anti-CCL3). The results represent experiments performed on 5 mice in each group. Scale bars indicate 50 μm. (B) Quantification of the number of F4/80-positive cells per 0.1 mm2 in the microscopic fields in the damaged site on day 4 after a femoral bone defect in uPA+/+ and uPA-/- mice treated with normal IgG or neutralizing anti-CCL3 antibody. The data represent the mean ± SEM of 5 mice. (C) Quantification of the bone defect area as assessed by qCT on days 1 and 4 in uPA+/+ and uPA-/- mice treated with normal IgG or neutralizing anti-CCL3 antibody. The data represent the mean ± SEM from 5 mice. **P < 0.01 and *P < 0.05 (Tukey’s test). Image collected and cropped by CiteAb from the following open publication (//dx.plos.org/10.1371/journal.pone.0123982), licensed under a CC-BY license. Not internally tested by R&D Systems.

Effects of neutralizing anti-CCL3 antibody on the number of macrophages at the damaged site and the decrease in area of bone defect on day 4 in uPA+/+ and uPA-/- mice.(A) Microphotographs of immunostaining for F4/80 at the damaged site on day 4 after a femoral bone defect in uPA+/+ and uPA-/- mice treated with normal IgG (Cont) or neutralizing anti-CCL3 antibody (Anti-CCL3). The results represent experiments performed on 5 mice in each group. Scale bars indicate 50 μm. (B) Quantification of the number of F4/80-positive cells per 0.1 mm2 in the microscopic fields in the damaged site on day 4 after a femoral bone defect in uPA+/+ and uPA-/- mice treated with normal IgG or neutralizing anti-CCL3 antibody. The data represent the mean ± SEM of 5 mice. (C) Quantification of the bone defect area as assessed by qCT on days 1 and 4 in uPA+/+ and uPA-/- mice treated with normal IgG or neutralizing anti-CCL3 antibody. The data represent the mean ± SEM from 5 mice. **P < 0.01 and *P < 0.05 (Tukey’s test). Image collected and cropped by CiteAb from the following open publication (//dx.plos.org/10.1371/journal.pone.0123982), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Mu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

CCL3/MIP-1 alpha Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant mouse CCL3/MIP-1 alpha (R&D Systems, Catalog # 450-MA)
  Ala24-Ala92
  Accession # Q5QNW0
• Specificity: Detects mouse CCL3/MIP-1 alpha in direct ELISAs and Western blots. In Western blots, less than 5% cross-reactivity with recombinant human (rh) MIP-1 beta , rhMIP-1 alpha , and recombinant mouse MIP-1 beta is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CCL3
• Purity Statement: Protein A or G purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.3-1 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 1 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL3/MIP-1 alpha Antibody [Unconjugated]

• C-C motif chemokine 3
• MIP1-(a)
• AI323804
• CCL3
• chemokine (C-C motif) ligand 3
• G0S19-1
• LD78a
• LD78alpha
• MIP1 alpha
• MIP-1 alpha
• MIP1A
• MIP-1alpha
• MIP1-alpha
• PAT 464.1
• SCYA3
• SIS-beta

Background

The macrophage inflammatory proteins 1 alpha and 1 beta , two closely related but distinct proteins, were originally co-purified from medium conditioned by a LPS-stimulated murine macrophage cell line. Mature mouse MIP-1 alpha shares approximately 77% and 70% amino acid identity with human MIP-1 alpha and mouse MIP-1 beta , respectively.
MIP‑1 proteins are expressed primarily in T cells, B cells, and monocytes after antigen or mitogen stimulation. The MIP-1 proteins are members of the beta (C-C) subfamily of chemokines.

Both MIP-1 alpha and MIP-1 beta are monocyte chemoattractants in vitro. Additionally, the MIP-1 proteins have been reported to have chemoattractant and adhesive effects on lymphocytes, with MIP-1 alpha and MIP-1 beta preferentially attracting CD8⁺ and CD4⁺ T cells, respectively. MIP-1 alpha has also been shown to attract B cells as well as eosinophils. MIP-1 proteins have been reported to have multiple effects on hematopoietic precursor cells and MIP-1 alpha  has been identified as a stem cell inhibitory factor that can inhibit the proliferation of hematopoietic stem cells in vitro as well as in vivo. In the same assays, MIP-1 beta was reported to be much less active. The functional receptor for MIP-1 alpha has been identified as CCR1 and CCR5.

1. Menten, P. et al. (2002) Cytokine Growth Factor Rev. 13:455.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CCL3/MIP-1 alpha Antibody (AB-450-NA)(7)

Publications using AB-450-NA

• Y Ishida, Y Kuninaka, M Nosaka, A Kimura, A Taruya, M Furuta, N Mukaida, T Kondo Prevention of CaCl2-induced aortic inflammation and subsequent aneurysm formation by the CCL3-CCR5 axis Nat Commun, 2020-11-25;11(1):5994. 2020-11-25 [PMID: 33239616] (In Vivo, Mouse)
• Hector R. Wong, J. Timothy Caldwell, Natalie Z. Cvijanovich, Scott L. Weiss, Julie C. Fitzgerald, Michael T. Bigham et al. Prospective clinical testing and experimental validation of the Pediatric Sepsis Biomarker Risk Model Science Translational Medicine 2019-11-13 [PMID: 31723040]
• G Liu, L Chen, Q Cai, H Wu, Z Chen, X Zhang, P Lu Streptozotocin?induced diabetic mice exhibit reduced experimental choroidal neovascularization but not corneal neovascularization Mol Med Rep, 2018-09-03;0(0):. 2018-09-03 [PMID: 30221697] (Western Blot, Mouse)
• Yi Li, Yuhuan Zheng, Tianshu Li, Qiang Wang, Jianfei Qian, Yong Lu et al. Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma Oncotarget 2015-09-15 [PMID: 26155942]
• Kawao N, Tamura Y, Horiuchi Y, Okumoto K, Yano M, Okada K, Matsuo O, Kaji H The Tissue Fibrinolytic System Contributes to the Induction of Macrophage Function and CCL3 during Bone Repair in Mice. PLoS ONE, 2015-04-20;10(4):e0123982. 2015-04-20 [PMID: 25893677] (Neutralization, Mouse)
• Alexandre Johannsen, Raphaël Genolet, Daniel F. Legler, Sanjiv A. Luther, Immanuel F. Luescher Definition of Key Variables for the Induction of Optimal NY-ESO-1–Specific T Cells in HLA Transgene Mice The Journal of Immunology 2010-09-15 [PMID: 20733200]
• Martinez de la Torre Y, Buracchi C, Borroni EM, Dupor J, Bonecchi R, Nebuloni M, Pasqualini F, Doni A, Lauri E, Agostinis C, Bulla R, Cook DN, Haribabu B, Meroni P, Rukavina D, Vago L, Tedesco F, Vecchi A, Lira SA, Locati M, Mantovani A Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc. Natl. Acad. Sci. U.S.A., 2007-02-05;104(7):2319-24. 2007-02-05 [PMID: 17283337] (Neutralization, Mouse)

Bioinformatics

• Gene Symbol: CCL3
• Uniprot:
  • Q5QNW0()